← All trials
NCT05686356
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 28, 2023
- Primary completion
- Sep 30, 2025
- Completion date
- Sep 30, 2025
- First posted
- Jan 17, 2023
- Last posted
- Nov 30, 2023
- Enrollment
- 352
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Aurum InstituteLead sponsor
- Sequella, Inc.Collaborator
- Global Alliance for TB Drug DevelopmentCollaborator
- National Institute for Medical Research, TanzaniaCollaborator
- Katholieke Universiteit LeuvenCollaborator
- Aurum InstituteOverall official - principal investigator
- Ludwig Maximilians UniversityCollaborator
- Stellenbosch UniversityCollaborator
- Government of MozambiqueCollaborator
- Wits Health Consortium (Pty) LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.